Bone alkaline phosphatase serum level predicts the response to antiandrogen withdrawal

European Urology

Volumn 41, Issue 3, 2002, Pages 257-261

  Morote, J ^a   Bellmunt, J ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Antiandrogen withdrawal; Bone alkaline phosphatase; Percent free prostatic specific antigen; Prostate cancer; Prostate specific antigen

Indexed keywords

ALKALINE PHOSPHATASE; ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ANTIGEN DETECTION; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; WITHDRAWAL SYNDROME;

AGED; ALKALINE PHOSPHATASE; ANDROGEN ANTAGONISTS; ANILIDES; FLUTAMIDE; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; TIME FACTORS;

EID: 0036522509     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00051-9     Document Type: Article

References (27)

1. Kelly WK, Scher HI. Prostate specific antigen decline after anti-androgen withdrawal: The flutamide withdrawal syndrome. J Urol 1993;149:607-9.
2. Small EJ, Carrol PR. Prostate-specific antigen decline after Casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome. Urology 1994;43:408-10.
3. Huan SD, Gerriden RG, Yau JC, Stewart DJ. Antiandrogen withdrawal syndrome with nilutamide. Urology 1997;49:632-4
4. Furuya Y, Akimoto S, Akakura K, Igarashi S, Shimazaki J, Ito H. Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer. Urol Int 1993;60:28-32.
5. Sella A, Flex D, Sulkes A, Baniel J. Antiandrogen withdrawal syndrome with cyproterone acetate. Urology 1998;52:1091-3.
6. Bissada NK, Kaczmarek AT. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. J Urol 1995;153:1944-5.
7. Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989;14:103-14.
8. Middleman MN, Lush RM, Figg WD. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate. Pharmacotherapy 1996;16:376-81.
9. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, et al. Prostate cancer cycle regulators: Response to antiandrogen withdrawal and development of antiandrogen independence. J Natl Cancer Inst 1999;91:1869-76.
10. Reese DM, Small EJ. Secondary hormonal manipulations in hormone refractory prostate cancer. Urol Clin North Am 1999;26:311-21.
11. Scher HI, Zhang Z, Cohen L, Kelly WK. Hormonaly relapsed prostatic cancer. Lessons from the flutamide withdrawal syndrome. Adv Urol 1995;8:61-95.
12. Kelly WK, Slovin SF, Scher HI. Steroid hormone withdrawal syndrome. Urol Clin North Am 1997;24:421-31.
13. Herrada J, Dieringer P, Logothetis CJ. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. J Urol 1996;155:620-3.
14. Sartor O, Cooper M, Weinberger M. Surprising activity of flutamide withdrawal, when combined with aminoglutetimide, in the treatment of hormonorrefractory prostate cancer. J Natl Cancer Inst 1994;86:222-7.
15. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 1995;76:1428-34.
16. Eisenberger MA, Reyno LM, Jodrell DI. Suramin, an active drug for prostate cancer: Interim observations in a phase I trial. J Natl Cancer Inst 1993;85:611-21.
17. Schellhammer PF, Venner P, Hass GP, Small EJ, Nieh PT, Seabaugh R, et al. Prostate specific decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 1997:157:1731-5.
18. Dupont A, Gomez J, Cusan L, Koutsilieris M, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993;150:908-13.
19. Figg WD, Sartor O, Cooper MR. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 1995;98:412-4.
20. Lorente JA, Morote J, Raventos C, Encabo G, Vañlenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996;155:1348-51.
21. Lorente JA, Valenzuela H, Morote J, Gelabert A. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 1999;26:625-32.
22. Morote J, Id M'Hammed Y. Martinez E, Esquena S, Lorente JA, Gelabert A. Increase of bone alkaline phosphatase after androgen deprivation therapy in patients with prostate cancer. Urology 2002;59:277-80.
23. Dupont A, Gomez J, Cusan L, Koutsilieris M, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993;150:908-13.
24. Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompikins A. Surprising activity of flutamide withdrawal, when combined with aminoglutetimide, in the treatment of hormone-refractory prostate cancer. J Natl Cancer Inst 1994;86:222-7.
25. de Voogt HJ, Suciu S, Sylvester R. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: Results from 2 European Organization for Research on Treatment of Cancer. J Urol 1989;141:883-8.
26. Small EJ, Carroll PR. Prostate-specific antigen decline after Casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome. Urology 1994;43:408-10.
27. Scher HI, Kelly WK. Flutamide withdrawel syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993;11:1566-71.